You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Hidradenitis Suppurativa: A Clinician's Tool for Early Diagnosis and Treatment

Beshara, Monica A. MSN, RN, NP-C, CWOCN

Advances in Skin & Wound Care:
doi: 10.1097/01.ASW.0000363559.53350.84
Features: Clinical Management Extra
Abstract

PURPOSE: To enhance the clinician's knowledge of the diagnosis and treatment of hidradenitis suppurativa (HS).

TARGET AUDIENCE: This continuing education activity is intended for physicians and nurses with an interest in skin and wound care.

OBJECTIVES: After participating in this educational activity, the participant should be better able to:

1. Assess and diagnose the pathophysiology and prevalence of HS.

2. Interpret the diagnostic process for HS.

3. Evaluate treatment options for HS.

In Brief

In this continuing education activity, the author reviews the prevalence and pathology of hidradenitis suppurativa and will teach clinicians how to diagnose and treat this chronic condition.

Author Information

Monica A. Beshara, MSN, RN, NP-C, CWOCN • Clinical Faculty • Georgia State University, Atlanta, Georgia

Ms Beshara has disclosed that she has no significant relationships with or financial interest regarding this educational activity. She has disclosed that she will present information on the off-label use of infliximab and adalimumab.

All staff and faculty, including spouses/partners (if any) in a position to control the content of this CME activity, have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity.

This continuing educational activity will expire for physicians on July 31, 2011.

This article originally appeared in May 2010 issue of The Nurse Practitioner. Beshara MA. Hidradenitis suppurativa: a clinician's tool for early diagnosis and treatment. Nurse Pract 2010;35(5):24-8.

© 2010 Lippincott Williams & Wilkins, Inc.